Metrics as of 10/15/2026, 10:45 PM (Berlin time), refresh in progress.
Cosmos Health Inc.
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce…
1D
-12.1%
1W
+7.0%
1M
+21.2%
6M
-17.1%
YTD
-32.4%
1Y
-73.1%
2Y
-56.7%
5Y
-99.7%
10Y
-99.7%
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~30% weaker price swings than usual
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
P/E
-0.51
P/B
0.98
EV/EBITDA
-2.46
RETURN ON EQUITY
-29.4%
NET MARGIN
-32.1%
DEBT/EQUITY
0.77
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
59.7%
FLOAT SHARES
60,064,269
AVG. DAILY VOLUME (30D)
3,751,821
Siokas Grigorios
Siokas Grigorios
Terzis Georgios
Terzis Georgios
Siokas Grigorios
Cosmos Health Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in Greece.
The CEO is Grigorios Siokas, the company employs around 163 people.
The IPO was on 23/07/2010; the stock trades on NASDAQ under the ticker COSM.
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -30% stronger than usual.
No, Cosmos Health currently does not pay a dividend.
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck &.
Clicking "Analyze stock" lets five strategies assess Cosmos Health against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.